THE USES OF ETHYL 2-(1H-BENZO[D]IMIDAZOL-2-YL)ACETATE TO SYNTHESIS PYRAZOLE, THIOPHENE, PYRIDINE AND COUMARIN DERIVATIVES WITH ANTITUMOR ACTIVITIES

Rafat M. Mohareb* and Marwa S. Gamaan

Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

(Received April 10, 2018; Revised June 15, 2018; Accepted July 12, 2018)

ABSTRACT. In the present work, the ethyl 2-(1H-benzo[d]imidazol-2-yl)acetate (3) was subjected to a series of heterocyclization reactions through its reaction with different chemical reagents. The resulting molecules were thiophene, pyrazole, coumarin derivatives incorporated benzo[d]imidazole moiety. All the synthesized compounds were determined by elemental analysis, 1H NMR, 13C NMR, and MS. The antitumor evaluations of the newly synthesized products toward the three cancer cell lines MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and SF-268 (CNS cancer) showed that compounds 5a, 9b, 9c, 17, 23b and 38 were of the highest potencies among the synthesized compounds.

KEY WORDS: Oxobutanamide, Thiophene, Pyrazole, Pyran, Pyridine

INTRODUCTION

In recent years, benzimidazole derivatives have provided a large number of biologically active compounds that have been intensively used in medicinal chemistry as drugs. They are structural isosteres of naturally occurring nucleotides, which allow them to interact easily with the biopolymers of the living system and different kinds of biological activity have been obtained. Some 2-aminobenzimidazoles displayed an appreciable antimicrobial effect. Their corresponding carbamate derivatives have been synthesized for their significant in vitro antifilarial activity [1]. Concerning the high affinity that they display towards a variety of enzymes and protein receptors, they could be considered as pivotal structures in drug design [2].

Figure 1. Examples of topoisomerase inhibitors containing benzimidazole nucleus.

Optimization of benzimidazole-based structures has resulted in marketed drugs, e.g. Omeprazole [3] and Pimobendan [4] that are therapeutically useful in the management of peptic ulcer and congestive heart failure respectively. Many derivatives of benzimidazoles are well known for their antimicrobial [5, 6] anthelmintic [7] antiviral [8, 9] and antifungal [10, 11] activities. Since 1985, benzimidazole containing compounds have been reported as well known anticancer agents [12, 13]. The role of mammalian DNA topoisomerases as molecular targets

*Corresponding author. E-mail: rafat_mohareb@yahoo.com
This work is licensed under the Creative Commons Attribution 4.0 International License
for anticancer drugs has been recognized. Some benzimidazoles have been reported as top isomerase inhibitors, e.g. Hoechst 33258 and Hoechst 33342 (Figure 1) [14, 15]. On extension of this work, head to head bis-benzimidazole compounds approved high efficacy as DNA binders [16]. Some widely used anticancer drugs such as RAF265 (CHIR-265; Novartis Pharmaceuticals, Basel, Switzerland) and AZD6244 (ARRY-142886; AstraZeneca, London, England) are known to contain benzimidazole moiety. RAF265 resulted in a reduction in tumor cell growth and in tumor cell apoptosis [17].

RESULTS AND DISCUSSION

In the present work, we synthesized a series of heterocyclic compounds derived from ethyl 2-(1H-benzo[d]imidazol-2-yl)acetate together with their antitumor evaluations. Thus, the reaction of o-phenylenediamine (1) with diethyl malonate (2) in an oil bath at 120 °C gave ethyl 2-(1H-benzo[d]imidazol-2-yl)acetate (3), its structure was based on analytical and spectral data. Compound 3 was used in many acyclic and heterocyclic reactions. Thus, compound 3 reacted with either aniline (4a) or 4-methylaniline (4b) to give the anilide derivatives 5a and 5b, respectively. The structures of compounds 5a and 5b were based on their respective analytical and spectral data. Thus, the 1H NMR spectrum 5a showed the presence of a singlet at δ 4.93 ppm corresponding to the CH2 group a multiplet at δ 7.25-7.41 ppm confirming the presence of the two phenyl protons and two signals at δ 8.26 and 8.32 ppm corresponding to the presence of the two NH groups. In addition the 13C NMR data showed beside the expected signals the presence of a signal at 54.2 for the CH2 group and two signals at 1.72 and 164.8 indicating the C=N and CO groups, respectively. Compound 3 reacted with any of benzaldehyde (6a), 4-methoxybenzaldehyde (6b) or 4-chlorobenzaldehyde (6c) to give the benzylidene derivatives 7a-c, respectively. Either of compound 7a with either hydrazine hydrate (8a) or phenylhydrazine (8b) or compound 7c with hydrazine hydrate gave the pyrazole derivatives 9a-c, respectively. Compound 7a reacted with malononitrile (10) to give the ethyl 1-amino-2-cyano-3-phenylbenzo[4,5]imidazol[1,2-alpyridine-4-carboxylate (11) (Scheme 1). The analytical and spectral data of compound 11 are in agreement with their respective analysis. Thus, the 1H NMR spectrum 11 showed (beside the expected signals) a triplet and quartet, a singlet (D2O exchangeable) at δ 4.83 ppm confirming the presence of the NH2 group. In addition the 13C NMR showed the presence of signals at 116.8 for the CN group, signals at 144.3, 143.2, 140.8, 137.3, 128.8, 126.2, 125.9, 125.4, 124.3, 123.5, 120.1, 119.3 equivalent to the pyridine C-2, C-3, C-4, C-5 and the C6H5, C5H4 groups.

The reactivity of compound 3 towards condensation reactions was studied in order to produce biologically active products. Thus, compound 3 reacted with acetyophenone (12) in an oil bath containing ammonium acetate to give the Knoevenagel condensation product 13. On the other hand, the reaction of compound 3 with either cyclopentanone (14a) or cyclohexanone (14b) gave the products 15a and 15b, respectively. The analytical and spectral data of 15a,b were in agreement with their respective structures. Thus, the 1H NMR spectrum of 15a showed (beside the expected signals) the presence the two multiplets at δ 1.18-1.24 and 2.9-2.21 ppm indicating the presence of the four cyclohexene CH2 groups and a singlet at δ 8.32 ppm (D2O exchangeable) indicating the presence of the NH group. The reaction of compound 3 with acetylacetonitrile (16) gave the benzo[4,5]imidazol[1,2-α]-pyridine derivative 17. Similarly, the reaction of compound 3 with malononitrile (10) gave the benzo[4,5]imidazol[1,2-α]-pyridine derivative 18.

Compound 3 reacted with hydrazinemethyl (8a) to give the hydrazide derivative 19. On the other hand the reaction of compound 3 with phenylisothiocyanate (20) gave the 1,2-dihydrobenzo[4,5]imidazol[1,2-c]-pyrimidin-3(4H)-one derivative 21 (Scheme 2). The structure of compound 21 was based on its analytical and spectral data. Thus, the 1H NMR spectrum 21...
showed the presence of a singlet at δ 5.90 ppm indicating the presence of the pyrimidine CH$_2$ group and a multiplet at δ 7.26-7.38 ppm for the C$_6$H$_5$ and C$_6$H$_4$ groups.

Scheme 1
The reactivity of compound 3 towards thiophene synthesis using the Gewald's thiophene synthesis was studied. Thus, the reaction of compound 3 with elemental sulfur and either of malononitrile (10) or ethyl cyanoacetate (22) gave the thiophene derivatives 23a and 23b, respectively. Moreover, the reaction of compound 3 with ethylorthoformate (24) gave the ethoxymethylyeno derivatives 25. On the other hand, the multi-component reaction of
compound 3 with ethyl orthoformate (24) and aniline (4a) gave the phenylaminomethylene derivative 26. The analytical and spectral data of compounds 25 and 26 were consistent with their respective structures (see experimental section). The multi-component reaction (MCRs) of compound 3 with ethyl orthoformate (24) and malononitrile (10) gave the ethyl 1-amino-2-cyano-3-ethoxybenzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate 28. Formation of the latter product took place through the intermediate formation of 28 followed by the Micheal type addition of the NH to the terminal CN group.

Scheme 3
The reaction of compound 3 with salicylaldehyde (29) in ethanol containing piperidine gave the coumarin derivative 30. The structure of compound 30 (Scheme 3) was based on analytical and spectral data. Thus, the $^1$H NMR spectrum 30 showed a singlet at $\delta$ 6.09 corresponding to the coumarin H-4 and a singlet at $\delta$ 8.09 (D$_2$O exchangeable) indicating the presence of the NH group. In addition the $^{13}$C NMR spectrum showed the presence of signals at 131.5, 130.3, 129.4, 128.2, 127.3, 126.8, 126.4, 125.3, 124.1, 123.6, 122.4, 121.6 equivalent to the two phenyl
groups and two signals at 173.4 and 164.6 indicating the presence of the C=N and C=O groups, respectively.

Further confirmations for the structure of compound 30 were obtained through studying its reactivity towards some chemical reagents. Thus, compound 30 reacted with either α-chloroacetone (31a) or ethyl α-chloroacetate (31b) to give the 1H-benzo[4,5]imidazo[1,2-a]chromeno[3,4-c]pyridin-1-one derivatives 32a and 32b, respectively. Formation of the latter product was explained in terms of the first reaction of the NH of compound 30 with the α-chloro group of 32a or 32b followed by either elimination of water or ethanol, respectively. Moreover, the reaction of compound 30 with chloroacetylchloride (33) gave the 8-hydroxy-1H-benzo[4,5]imidazo[1,2-a]chromeno[3,4-c]pyridin-1-one 35 as its analytical and spectral data confirm the proposed structure. The reaction of compound 30 with acetic anhydride (36) gave the N-acetyl derivative 37. Our trials to make cyclization of 37 under different conditions were failed. Finally, the reaction of compound 30 with phenylisothiocyanate (20) gave the N-phenylthiourea derivative 38 (Scheme 4).

Antitumor and normal cell line activity tests

Reagents. Fetal bovine serum (FBS) and L-glutamine, were from Gibco Invitrogen Co. (Scotland, UK). RPMI-1640 medium was from Cambrex (New Jersey, USA). Dimethyl sulfoxide (DMSO), doxorubicin, penicillin, streptomycin and sulforhodamine B (SRB) were from Sigma Chemical Co. (Saint Louis, USA).

Cell cultures. Three human tumor cell lines, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and SF-268 (CNS cancer) were used. MCF-7 was obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK), NCI-H460, SF-268 and normal fibroblast cells (WI 38) were kindly provided by the National Cancer Institute (NCI, Cairo, Egypt). They grow as monolayer and routinely maintained in RPMI-1640 medium supplemented with 5% heat inactivated FBS, 2 µM glutamine and antibiotics (penicillin 100 U/mL, streptomycin 100 µg/mL), at 37 °C in a humidified atmosphere containing 5% CO2. Exponentially growing cells were obtained by plating 1.5 x 10^5 cells/mL for MCF-7 and SF-268 and 0.75 x 10^4 cells/mL for NCI-H460, followed by 24 h of incubation. The effect of the vehicle solvent (DMSO) on the growth of these cell lines was evaluated in all the experiments by exposing untreated control cells to the maximum concentration (0.5%) of DMSO used in each assay.

Tumor cell growth assay. The effects of the synthesized compounds on the in vitro growth of human tumor cell lines were evaluated according to the procedure adopted by the National Cancer Institute (NCI, USA) in the ‘In vitro Anticancer Drug Discovery Screen’ that uses the protein-binding dye sulforhodamine B to assess cell growth. Briefly, exponentially, cells growing in 96-well plates were then exposed for 48 h to five serial concentrations of each compound, starting from a maximum concentration of 150 μM. Following this exposure period adherent cells were fixed, washed, and stained. The bound stain was solubilized and the absorbance was measured at 492 nm in a plate reader (Bio-Tek Instruments Inc., Power wave XS, Wincoski, USA). For each test compound and cell line, a dose–response curve was obtained and the growth inhibition of 50% (GI50), corresponding to the concentration of the compounds that inhibited 50% of the net cell growth was calculated as described elsewhere. Doxorubicin was used as a positive control and tested in the same manner.

Results are given in concentrations that were able to cause 50% of cell growth inhibition (GI50) after a continuous exposure of 48 h and show means ± SEM of three-independent experiments performed in duplicate.

Bull. Chem. Soc. Ethiop. 2018, 32(3)
Structure activity relationship

It is clear from Table 1 that many of the synthesized compounds showed high activity against the three cancer cell lines. It is obvious that compound 5a showed higher potency than compound 5b as it seemed that the presence of the 4-methylphenyl group responsible for the decreasing of compound 5b. On the other hand the compounds 7a-c showed low potencies against the three cancer cell lines. Considering the pyrazole derivatives 9a-c, it is obvious that compounds 9b (R = H, X = Cl) and compound 9c (R = Ph, X = H) revealed high potencies against the three cancer cell lines whereas compound 11 showed low inhibitions. Considering compounds 13, 5a,b and 17 it is clear that the ethyl 1,3-dimethylbenzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate (17) showed the highest inhibitions among the four compounds. The same also for compounds 18, 19, 21, 23a and 23b, it is clear that compound 23b showed the highest inhibitions and its reactivity was due to the presence the COOEt group attached to the thiophene ring. Considering compounds 25, 26, 28 and 30, it is clear that compound 30 was the only one with high potencies. For compounds 32a, 32b, 37 and 38 it is obvious from Table 1 that the 2-(2-oxo-2H-chromen-3-yl)-N-phenyl-1H-benzo[d]imidazole-1-carbothioamide 38 was of the highest potency among these four compounds. Its reactivity is attributed to the presence of the coumarin and the N-phenylthiourea moiety.

Table 1. Effect of the newly synthesized compounds on growth of three human tumor cells.

| Compound | GI_{50} (μmol L^{-1}) |
|----------|----------------------|
|          | MCF-7 | NCI-H460 | SF-268 | WI 38 |
| 3        | 23.6 ± 4.1 | 34.6 ± 12.1 | 45.4 ± 2.2 | >100 |
| 5a       | 0.21 ± 0.04 | 0.12 ± 0.04 | 0.08 ± 0.006 | 40.0 ± 1.3 |
| 5b       | 36.6 ± 10.2 | 33.0 ± 8.6 | 38.6 ± 8.0 | >100 |
| 7a       | 23.2 ± 2.4 | 26.6 ± 2.8 | 22.8 ± 8.5 | 38.2 ± 2.6 |
| 7b       | 22.4 ± 5.8 | 26.7 ± 8.2 | 31.4 ± 2.4 | 18.6 ± 0.0 |
| 7c       | 20.8 ± 8.30 | 22.8 ± 4.32 | 22.8 ± 6.23 | >100 |
| 9a       | 38.2 ± 3.6 | 36.3 ± 12.5 | 40.6 ± 8.8 | >100 |
| 9b       | 0.01 ± 0.001 | 0.02 ± 0.006 | 0.06 ± 0.002 | >100 |
| 9c       | 0.02 ± 0.001 | 0.03 ± 0.008 | 0.06 ± 0.008 | >100 |
| 11       | 30.0 ± 1.4 | 20.8 ± 4.3 | 20.3 ± 2.8 | >100 |
| 13       | 12.6 ± 0.1 | 18.6 ± 6.06 | 30.4 ± 2.36 | 30.6 ± 10.2 |
| 15a      | 32.6 ± 1.3 | 29.7 ± 1.6 | 20.2 ± 8.9 | 55.8 ± 8.7 |
| 15b      | 22.4 ± 2.10 | 10.4 ± 3.0 | 8.63 ± 2.8 | >100 |
| 17       | 0.08 ± 0.002 | 0.08 ± 0.003 | 0.02 ± 0.002 | >100 |
| 18       | 38.1 ± 1.0 | 27.8 ± 4.3 | 12.3 ± 2.4 | >100 |
| 19       | 38.4 ± 8.3 | 29.3 ± 10 | 36.40 ± 2.13 | 60.1 ± 2.3 |
| 21       | 13.8 ± 2.6 | 12.1 ± 4.2 | 29.2 ± 4.1 | >100 |
| 23a      | 2.82 ± 2.8 | 6.9 ± 2.2 | 3.0 ± 1.8 | 77.5 ± 5.1 |
| 23b      | 0.06 ± 0.007 | 0.06 ± 0.006 | 0.02 ± 0.008 | >100 |
| 25       | 21.2 ± 4.2 | 30.0 ± 8.0 | 20.59 ± 4.01 | >100 |
| 26       | 21.2 ± 6.1 | 24.0 ± 4.7 | 10.39 ± 6.80 | >100 |
| 28       | 32.0 ± 7.3 | 26.7 ± 2.8 | 30.4 ± 2.9 | 32.6 ± 6.4 |
| 30       | 1.2 ± 0.4 | 0.3 ± 0.16 | 2.8 ± 0.06 | 22.4 ± 1.6 |
| 32a      | 26.6 ± 8.5 | 29.3 ± 12.3 | 18.4 ± 2.8 | 68.2 ± 2.0 |
| 32b      | 24.1 ± 10.4 | 30.8 ± 10.8 | 26.1 ± 2.8 | 25.2 ± 0.8 |
| 35       | 44.4 ± 4.31 | 29.03 ± 8.01 | 20.6 ± 4.0 | 28.2 ± 8.2 |
| 37       | 22.7 ± 6.2 | 36.5 ± 6.4 | 31.5 ± 8.0 | >100 |
| 38       | 0.08 ± 0.004 | 0.05 ± 0.002 | 0.06 ± 0.001 | 28.0 ± 4.9 |
| Doxorubicin | 0.04 ± 0.008 | 0.09 ± 0.008 | 0.09 ± 0.007 | >100 |

Bull. Chem. Soc. Ethiop. 2018, 32(3)
From Table 1 it is clear that the cytotoxic effect of the cyclic compounds. Compounds 5a, 9a, 9b, 17, 23a, 23b, 30, 38 exhibited optimal cytotoxic effect against cancer cell lines, with GI\textsubscript{50} values in the μM range. On the other hand, compounds 11, 13, 15a, 15b, 18, 19, 21, 25, 27, 29, 32a, 32b, 35 and 37 showed low cytotoxicity effect toward the three cancer lines. It is clear from the demonstrated “SAR” that the presence of electron-negative groups together with the nature of the heteroatom enhances the antitumor effect of the target molecules.

![Figure 2. GI\textsubscript{50} of the new synthesized compounds against MCF-7, NCI-H460, SF-268 and WI-38.](image)

**EXPERIMENTAL**

**General**

All melting points were determined on an electrothermal apparatus (Büchi 535, Switzerland) in an open capillary tube and are uncorrected. \textsuperscript{13}C-NMR and \textsuperscript{1}H-NMR spectra were recorded on Bruker DPX200 instrument in DMSO with TMS as internal standard for protons and solvent signals as internal standard for carbon spectra. Chemical shift values are mentioned in δ (ppm). Mass spectra were recorded on EIMS (Shimadzu) and ESI-esquire 3000 Bruker Daltonics instrument. Elemental analyses were carried out by the Microanalytical Data Unit Ludwig-Maximilians-Universitat-Munchen, Germany. The progress of all reactions was monitored by TLC on 2 x 5 cm pre-coated silica gel 60 F254 plates of thickness of 0.25 mm (Merck).

**Ethyl 2-(1H-benzo[d]imidazol-2-yl)acetate (3)**

To the dry solid of \textalpha-phenylene diamine (1.08 g, 0.01 mol) diethylmalonate (1.60 g, 0.01 mol) was added. The reaction mixture was heated in an oil bath at 120 °C for 1 h then left to cool. The remaining product was triturated with ethanol and the formed solid product was collected by filtration. Brown crystals from ethanol; yield: 1.73 g (85%); m.p. 130 °C. IR, ν: 3465-3328 (NH), 3058 (CH aromatic), 2973, 2848 (CH\textsubscript{3}, CH\textsubscript{2}), 1703 (C=O), 1640 (C=N), 1615 (C=C). \textsuperscript{1}H-
NMR, δ: 1.14 (t, 3H, J = 6.85 Hz, CH₃), 4.26 (q, 2H, J = 6.85 Hz), 4.82 (s, 2H, CH₂), 7.28-7.39 (m, 4H, C₆H₄), 8.30 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO): 16.2 (ester CH₃), 52.8 (ester CH₂), 54.3 (CH₂), 121.4, 122.8, 123.6, 124.3, 126.4, 126.8 (C₆H₅), 172.8 (C=O); Anal. calcd for C₈H₉N₂O₂: C, 64.69; H, 5.92; N, 13.72%. Found: C, 64.48; H, 6.20; N, 13.80%. MS: m/z: (%) 204 (M⁺, 33%).

General procedure for the synthesis of the anilide derivatives 5a,b

To a solution of compound 3 (2.04 g, 0.01 mol) in dimethylformamide (30 mL) either aniline (0.93 g, 0.01 mol) or 4-methylaniline (1.08 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 4 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration.

2-(1H-Benz[e]imidazol-2-yl)-N-phenylacetamide (5a). Light brown crystals from ethanol; yield: 2.08 g (80%); m.p. 220-222 °C. IR: v: 3472-3324 (2NH), 3050 (CH aromatic), 1680 (C=O), 1648 (C=N), 1629 (C=O). ¹H-NMR, δ: 4.93 (s, 2H, CH₂), 7.25-7.41 (m, 9H, C₆H₅, C₆H₄); 4.26 (q, 2H, J = 6.85 Hz), 4.82 (s, 2H, CH₂, D₂O exchangeable). ¹³C NMR (DMSO): 54.8 (CH₂), 119.2, 120.8, 122.8, 123.6, 124.3, 125.2, 126.1, 127.3, 128.3, 129.2, 131.6, 148.4 (CO), 71.7 (C=N); Anal. calcd for C₁₅H₁₄N₂O: C, 72.38; H, 5.66; N, 15.69%. Found: C, 72.38; H, 5.66; N, 15.69%. MS: m/z: (%) 251 (M⁺, 24%).

General procedure for the synthesis of the benzylidene derivatives 7a-c

To a solution of compound 3 (2.04 g, 0.01 mol) in ethanol (30 mL) containing piperidine (0.50 mL) either benzaldehyde (1.06 g, 0.01 mol) or 4-methoxy benzaldehyde (1.31 g, 0.01 mol) or 4-chlorobenzaldehyde (1.34 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 3 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration.

Ethyl 2-(1H-benzo[d]imidazol-2-yl)-3-phenylacrylate (7a). Gray crystals from ethanol; yield: 2.45 g (77%); m.p. > 300 °C. IR: v: 3478-3329 (NH), 3057 (CH aromatic), 2962, 2873 (CH₃, CH₂), 1688 (C=O), 1646 (C=N), 1630 (C=O). ¹H-NMR: δ: 1.14 (t, 3H, J = 7.66 Hz, CH₃), 4.21 (q, 2H, J = 7.66 Hz, CH₂), 6.24 (s, 1H, CH=CH), 7.29-7.38 (m, 9H, C₆H₅, C₆H₄), 8.26 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO): 16.3 (ester CH₃), 52.5 (ester CH₂), 89.3, 90.2 (CH=CH), 120.6, 122.1, 123.2, 123.9, 124.1, 124.6, 125.8, 127.8, 128.2, (C₆H₅, C₆H₄), 164.8 (CO), 172.6 (C=O); Anal. calcd for C₁₇H₁₆N₂O₂: C, 73.95; H, 5.52; N, 9.58%. Found: C, 72.73; H, 5.49; N, 9.37%. MS: m/z: (%) 292 (M⁺, 64%).

Ethyl 2-(1H-benzo[d]imidazol-2-yl)-3-(4-methoxyphenyl)acrylate (7b). Light brown crystals from ethanol; yield: 2.22 g (69%); m.p. 151 °C. IR: v: 3484-3362 (NH), 3055 (CH aromatic), 2949, 2868 (CH₃, CH₂), 1686 (C=O), 1640 (C=N), 1626 (C=O). ¹H-NMR: δ: 1.16 (t, 3H, J = 7.08 Hz, CH₃), 3.14 (s, 3H, CH₃), 4.23 (q, 2H, J = 7.08 Hz, CH₂), 6.26 (s, 1H, CH=CH), 7.27-7.36 (m, 8H, 2C₆H₅), 8.26 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO): 16.4 (ester CH₃), 53.8 (OCH₃), 52.3 (ester CH₂), 89.1, 90.4 (CH=CH), 120.3, 122.8, 123.0, 123.7, 124.4, 125.8, 172.8 (C=O); Anal. calcd for C₂₉H₂₄O₄: C, 74.08; H, 4.91; O, 21.01%. Found: C, 73.85; H, 4.92; O, 21.08%. MS: m/z: (%) 436 (M⁺, 33%).
126.3, 127.6, 128.2, 129.4 (C₆H₅, C₆H₄), 164.6 (CO), 172.6 (C=N); Anal. calcd for C₁₃H₁₃N₂O₂: C, 70.79; H, 5.63; N, 8.69%. Found: C, 70.82; H, 5.73; N, 8.59%. MS: m/z: (%) 322 (M⁺, 83%).

**Ethyl 2-(1H-benzof][imidazol-2-yl)-3-(4-chlorophenyl)acrylate (7c).** Yellow crystals from ethanol; yield: 2.61 g (80%); m.p. 103 °C. IR, v: 3477-3349 (NH), 3054 (CH aromatic), 2933, 2863 (CH₂, CH₃), 1689 (C=O), 1644 (C=N), 1631 (C=C). ¹H-NMR: δ: 1.14 (t, 3H, J = 7.27 Hz, CH₃), 4.21 (q, 2H, J = 7.27 Hz, CH₂), 6.24 (s, 1H, CH=C), 7.24-7.39 (m, 8H, 2 C₆H₄), 8.29 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO): 16.3 (ester CH₂), 52.2 (ester CH₂), 89.5, 90.1 (CH=C), 120.3, 122.7, 124.8, 125.2, 126.4, 127.4, 127.9, 128.3, 128.6 (C₆H₅, C₆H₄), 164.5 (CO), 172.4 (C=N); Anal. calcd for C₂₃H₂₁CIN₂O₂: C, 66.16; H, 4.63; N, 8.57%. Found: C, 66.09; H, 4.83; N, 8.59%. MS: m/z: (%) 326 (M⁺, 60%).

**General procedure for the synthesis of the pyrazole derivatives 9a-c**

To a solution of either compound 7a (3.22 g, 0.01 mol) with either of hydrazine hydrate (0.50 g, 0.01 mol) or phenylhydrazine (1.08 g, 0.01 mol) or compound 7c (3.26 g, 0.01 mol) with hydrazine hydrate (0.50 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 6 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration.

**4-(1H-Benzof][imidazol-2-yl)-5-phenyl-1H-pyrazol-3-ol (9a).** Light brown crystals from ethanol; yield: 2.32 g (84%); m.p. 106 °C. IR, v: 3569-3329 (OH, 2NH), 3055 (CH aromatic), 1644 (C=N), 1630 (C=C). ¹H-NMR: δ: 3.72-7.42 (m, 9H, C₆H₅, C₆H₄), 8.27, 8.31 (2s, 2H, 2NH, D₂O exchangeable), 10.28 (s, 1H, OH, D₂O exchangeable). ¹³C NMR (DMSO): 142.6, 143.8 (pyrazole C-4, C-5), 119.8, 120.5, 122.8, 123.6, 124.1, 124.5, 126.8, 127.1, 129.4, 130.6 (C₆H₅, C₆H₄), 172.6, 176.2 (2C=N); Anal. calcd for C₂₃H₂₁N₂O: C, 69.55; H, 4.38; N, 20.28%. Found: C, 69.73; H, 4.51; N, 20.37%. MS: m/z: (%) 276 (M⁺, 38%).

**4-(1H-Benzof][imidazol-2-yl)-5-(4-chlorophenyl)-1H-pyrazol-3-ol (9b).** Light brown crystals from ethanol; yield: 2.45 g (79%); m.p. 208-211 °C. IR, v: 3523-3321 (OH, 2NH), 3055 (CH aromatic), 1646 (C=N), 1630 (C=C). ¹H-NMR: δ: 7.22-7.39 (m, 9H, C₆H₅, C₆H₄), 8.29, 8.33 (2s, 2H, 2NH, D₂O exchangeable), 10.26 (s, 1H, OH, D₂O exchangeable). ¹³C NMR (DMSO): 143.9, 142.4 (pyrazole C-4, C-5), 119.6, 120.8, 123.3, 123.9, 124.2, 124.8, 126.8, 128.9, 129.4, 130.8 (C₆H₅, C₆H₄), 176.4, 172.5 (2C=N); Anal. calcd for C₂₃H₂₁CIN₂O: C, 61.84; H, 3.57; N, 18.03%. Found: C, 61.95; H, 3.84; N, 17.89%. MS: m/z: (%) 310 (M⁺, 30%).

**4-(1H-Benzof][imidazol-2-yl)-1,5-diphenyl-1H-pyrazol-3-ol (9c).** Yellow crystals from 1,4-dioxane; yield: 2.32 g (66%); m.p. 152-154 °C. IR, v: 3520-3349 (OH, NH), 3053 (CH aromatic), 1642 (C=N), 1633 (C=C), 8.25 (s, 1H, NH, D₂O exchangeable), 10.29 (s, 1H, OH, D₂O exchangeable). ¹³C NMR (DMSO): 144.2, 142.6 (pyrazole C-4, C-5), 119.9, 120.3, 123.1, 123.6, 124.1, 124.3, 125.2, 125.3, 126.8, 127.0, 127.6, 128.2, 130.8 (C₆H₅, C₆H₄), 175.2, 172.7 (2C=N); Anal. calcd for C₂₅H₂₁N₂O: C, 74.98; H, 4.58; N, 15.90%. Found: C, 75.22; H, 4.72; N, 15.73%. MS: m/z: (%) 352 (M⁺, 21%).

**Ethyl 1-alkyl-2-cyano-3-phenylbenzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate (11)**

To a solution of compound 6a (3.33 g, 0.01 mol) in ethanol (40 mL) containing triethylamine (0.50 mL), malononitrile (0.66 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 6 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration. Yellow crystals from 1,4-dioxane; yield: 2.42 g (80%); m.p. 82 °C. IR, v: 3488-3433 (NH), 3056 (CH aromatic), 2927, 2860 (CH₃, CH₂), 2225 (CN), 1687 (CO), 1640 (C=N), 1636 (C=C). ¹H-NMR: δ: 1.15 (t, 3H, J = 6.89 Hz, CH₃), 2.80 (t, 2H, J = 6.89 Hz, CH₂), 3.75 (s, 3H, OCH₃), 7.32-7.78 (m, 7H, C₆H₅). Found: C, 75.22; H, 4.72; N, 15.73%. MS: m/z: (%) 352 (M⁺, 21%).
4.23 (q, 2H, J = 6.89 Hz, CH₂), 4.83 (s, 2H, NH₂, D₂O exchangeable), 7.28-7.42 (m, 9H, C₆H₅, C₆H₆). ¹³C NMR (DMSO): 16.4 (ester CH₂), 52.5 (ester CH₂), 116.8 (CN), 119.3, 120.1, 123.5, 124.3, 125.4, 125.9, 126.2, 128.8, 137.3, 140.8, 144.3, 143.2, (pyridine C-2, C-3, C-4, C-5, C₆H₅, C₆H₆), 164.8 (CO), 172.4 (C=N); Anal. calcld for C₂₁H₁₆N₂O₂: C, 70.77; H, 4.53; N, 15.72%. Found: C, 70.93; H, 4.70; N, 15.63%. MS m/z (%): 356 (M⁺, 38%).

Ethyl 2-(1H-benzo[d]imidazol-2-yl)-3-phenylbut-2-enoate (13)

To the dry solid of compound 3 (2.04 g, 0.01 mol) ammonium acetate (0.50 g) and acetylacetone (1.00 g, 0.01 mol) were added. The reaction mixture was heated in an oil bath at 120 °C for 30 min then left to cool. The product was triturated with ethanol and the formed solid product was collected by filtration. Pale yellow crystals from 1,4-dioxane; yield: 1.69 g (69%); m.p. 286 (C-N), 1638 (C=C). ¹H-NMR: δ: 1.15 (t, 3H, J = 7.16 Hz, CH₃), 1.13-1.18 (m, 4H, 2CH₂), 2.08-2.16 (m, 6H, 3CH₂), 4.22 (q, 2H, J = 7.16 Hz, CH₂), 7.23-7.36 (m, 4H, C₆H₅), 8.30 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO): 16.2 (ester CH₂), 52.2 (ester CH₂), 86.4, 90.6 (C=C), 120.3, 121.2, 123.2, 123.8, 124.1, 125.3, 128.6, 129.4 (C₆H₅, C₆H₆), 164.5 (CO), 173.1 (C=N); Anal. calcld for C₁₇H₁₈N₂O₂: C, 71.09; H, 6.61; N, 10.36%. Found: C, 70.93; H, 6.93; N, 10.47%. MS: m/z (%): 270 (M⁺, 36%).

General procedure for the synthesis of the ylidene derivatives 15a, b

To the dry solid of compound 3 (2.04 g, 0.01 mol) ammonium acetate (0.50 g) either cyclohexanone (0.92 g, 0.01 mol) or cyclopentanone (0.78 g, 0.01 mol) were added. The reaction mixture was heated in an oil bath at 120 °C for 1 h then left to cool. The product was triturated with ethanol and the formed solid product was collected by filtration.

Ethyl 2-(1H-benzo[d]imidazol-2-yl)-2-cyclopentylidylenecacetate (15a). Pale yellow crystals from ethanol; yield: 2.53 g (83%); m.p. 155 °C. IR, v: 3463-3379 (NH), 3057 (CH aromatic), 2955, 2863 (CO), 1638 (C=N), 1630 (C=C). ¹H-NMR: δ: 1.18 (m, 4H, 2CH₂), 2.19-2.21 (m, 4H, 2CH₂), 4.22 (q, 2H, J = 7.16 Hz, CH₂), 7.27-7.38 (m, 4H, C₆H₅), 8.32 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO): 16.2 (ester CH₂), 1.89-2.13 (2m 4CH₂), 52.6 (ester CH₂), 86.4, 90.6 (C=C), 120.3, 121.2, 123.2, 125.6, 128.6 (C₆H₅, C₆H₆), 164.8 (CO), 173.2 (C=N); Anal. calcld for C₁₇H₁₈N₂O₂: C, 71.09; H, 6.61; N, 10.36%. Found: C, 70.93; H, 6.93; N, 10.47%. MS: m/z (%): 270 (M⁺, 36%).

Ethyl 2-(1H-benzo[d]imidazol-2-yl)-2-cyclohexyldiylenecacetate (15b). Gray crystals from ethanol; yield: 2.33 g (77%); m.p. 120 °C. IR, v: 3463-3379 (NH), 3048 (CH aromatic), 2929, 2868 (CH₃, CH₂), 1688 (CO), 1632 (C=N), 1628 (C=C). ¹H-NMR: δ: 1.15 (t, 3H, J = 7.16 Hz, CH₃), 1.13-1.18 (m, 4H, 2CH₂), 2.08-2.16 (m, 6H, 3CH₂), 4.22 (q, 2H, J = 7.16 Hz, CH₂), 7.23-7.36 (m, 4H, C₆H₅), 8.30 (s, 1H, NH, D₂O exchangeable). Anal. calcld for C₁₇H₁₈N₂O₂: C, 71.81; H, 7.09; N, 9.85%. Found: C, 71.63; H, 6.87; N, 9.62%. MS: m/z (%): 284 (M⁺, 19%).

Ethyl 1,3-dimethylbenzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate (17)

To a solution of compound 3 (2.04 g, 0.01 mol) in ethanol (40 mL) containing piperidine (0.50 mL), acetylacetone (1.00 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 2 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration. Brown crystals from ethanol; yield: 1.67 g (73%); m.p. 233 °C. IR, v: 3056 (CH aromatic), 2925, 2863 (CH₃, CH₂), 1684 (C=N), 1631 (C=C). ¹H-NMR: δ: 1.13 (t, 3H, J = 7.22 Hz, CH₃), 2.89, 2.93 (2x, 6H, 2CH₃), 4.22 (q, 2H, J = 7.22 Hz, CH₂), 6.14 (s, 1H, pyridine H-3), 7.25-7.39 (m, 4H, C₆H₅). ¹³C NMR

Bull. Chem. Soc. Ethiop. 2018, 32(3)
(DMSO): 16.6 (ester CH$_2$), 23.8, 24.6 (2CH$_3$), 52.5 (ester CH$_2$), 121.2, 123.4, 124.8, 126.5, 128.6, 129.4, 139.3, 141.8, 142.2, 142.6 (pyridine, C$_3$H$_2$), 164.3 (CO), 173.3 (C=N); Anal. calcd for C$_3$H$_7$N$_2$O$_2$: C, 71.62; H, 6.01; N, 10.44%. Found: C, 71.80; H, 5.82; N, 10.63%. MS: m/z (%) 268 (M$^+$, 37%).

**Ethyl 1,3-diaminobenzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate (18)**

To a solution of compound 3 (2.04 g, 0.01 mol) in ethanol (40 mL) containing piperidine (0.50 mL), malononitrile (0.66 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 4 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration. Yellow crystals from ethanol; yield: 1.13 g, 0.01 mol) were added. The reaction mixture was heated under reflux for 6 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration. Yield: 2.67 g (87%); m.p. 202°C.

**General procedure for the synthesis of the thiophene derivatives 23a,b**

To a solution of compound 3 (2.04 g, 0.01 mol) in ethanol (40 mL) containing triethylamine (0.50 mL) elemental sulfur or either of malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) were added. The reaction mixture was heated under reflux for 4 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration.
2-Amino-5-(1H-benzo[d]imidazol-2-yl)-4-hydroxythiophene-3-carbonitrile (23a). Dark brown crystals from ethanol; yield: 2.61 g (87%); m.p. 252°C. IR, ν: 3572-3341 (OH, NH₂, NH), 3054 (CH aromatic), 2220 (CN), 1646 (C=O), 1628 (C=C). ¹H-NMR: δ: 5.21 (s, 2H, NH₂, D₂O exchangeable), 7.31-7.59 (m, 4H, C₆H₄), 8.22 (s, 1H, NH, D₂O exchangeable), 10.15 (s, 1H, OH, D₂O exchangeable). ¹³C NMR (DMSO): 116.8 (CN), 122.1, 121.3, 123.2, 125.3, 127.2, 128.7 (C₆H₅), 173.4 (C=O). Anal. calcd for C₁₂H₁₂N₂Os: C, 64.60; H, 6.20; N, 10.76%. Found: C, 64.81; H, 5.93; N, 10.59%. MS: m/z (%): 260 (M⁺, 42%).

Ethyl 2-amino-5-(1H-benzo[d]imidazol-2-yl)-4-hydroxythiophene-3-carboxylate (23b). Black crystals from ethanol; yield: 2.89 g (87%); m.p. 249°C. IR, ν: 3559-3321 (OH, NH₂, NH), 3058 (CH aromatic), 2977, 2857 (CH₃, CH₂), 1688 (CO), 1643 (C=O), 1629 (C=C). ¹H-NMR: δ: 1.14 (t, 3H, J = 7.42 Hz, CH₃), 4.22 (q, 2H, J = 7.42 Hz, CH₂), 5.14 (s, 2H, NH₂, D₂O exchangeable), 7.27-7.37 (m, 4H, C₆H₄), 8.24 (s, 1H, NH, D₂O exchangeable), 10.32 (s, 1H, OH, D₂O exchangeable). Anal. calcd for C₁₄H₁₄N₂O₃S: C, 55.43; H, 4.32; N, 13.85; S, 10.57%. Found: C, 55.22; H, 4.62; N, 14.09; S, 10.64%. MS: m/z (%): 303 (M⁺, 52%).

Ethyl 2-(1H-benzo[d]imidazol-2-yl)-3-ethoxycarboxylic acid (25)

To a solution of compound 3 (2.04 g, 0.01 mol) in ethanol (40 mL) containing piperidine (0.50 mL) ethyl orthoformate (1.48 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 6 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration. Yellow crystals from ethanol; yield: 2.22 g (68 %); m.p. >300°C. IR, ν: 3489-3351 (NH), 3057 (CH aromatic), 2983, 2866 (CH₃, CH₂), 1704 (CO), 1646 (C=N), 1624 (C=C). ¹H-NMR: δ: 1.11, 1.13 (2t, 6H, J = 6.67 Hz), 2.04 (q, 4H, J = 7.03 Hz, 2CH₂), 3.83, 4.20 (2q, 4H, J = 6.67 Hz, 2CH₂), 6.08 (s, 1H, CH=C), 7.23-7.39 (m, 4H, C₆H₄), 8.21 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO): 16.3, 16.5 (two OCH₂CH₃), 52.3, 52.8 (two OCH₂CH₃), 86.4, 90.8 (CH=O), 121.5, 122.9, 125.1, 126.4, 127.2, 128.6 (C₆H₄), 164.5 (CO), 173.8 (C=O); Anal. calcd for C₁₃H₁₄N₂O₂: C, 64.60; H, 6.20; N, 10.76%. Found: C, 64.81; H, 5.93; N, 10.59%. MS: m/z (%): 260 (M⁺, 42%).

Ethyl 2-(1H-benzo[d]imidazol-2-yl)-3-(phenylamino)acrylic acid (26)

To a solution of compound 3 (2.04 g, 0.01 mol) in ethanol (40 mL) containing piperidine (0.50 mL) ethyl orthoformate (1.48 g, 0.01 mol) and aniline oil (0.93 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 3 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration. Pale yellow crystals from ethanol; yield: 2.35 g (79%); m.p. >300°C. IR, ν: 3471-3329 (NH), 3055 (CH aromatic), 2980, 2873 (CH₃, CH₂), 1699 (CO), 1643 (C=N), 1629 (C=C). ¹H-NMR: δ: 1.15 (t, 3H, J = 7.13 Hz, CH₃), 4.23 (q, 2H, J = 7.13 Hz, CH₂), 6.03 (s, 1H, CH=C), 7.26-7.42 (m, 9H, C₆H₅, C₆H₄), 8.23, 8.34 (2s, 2H, 2NH, D₂O exchangeable). ¹³C NMR (DMSO): 16.2 (ester CH₃), 52.5 (ester CH₂), 88.4, 90.3 (C=C), 120.6, 121.6, 123.6, 123.8, 124.1, 125.3, 126.4, 127.3, 128.8, 129.5 (C₆H₅, C₆H₄), 164.8 (CO), 173.3 (C=N); Anal. calcd for C₁₈H₁₄N₂O₃: C, 70.34; H, 5.58; N, 13.67%. Found: C, 70.29; H, 5.73; N, 13.82%. MS: m/z (%): 307 (M⁺, 22%).

Ethyl 1-amino-2-cyano-3-ethoxybenzo[4,5]imidazo[1,2-a]pyridine-4-carboxylate (28)

To a solution of compound 3 (2.04 g, 0.01 mol) in ethanol (40 mL) containing piperidine (0.50 mL) ethyl orthoformate (1.48 g, 0.01 mol) and malononitrile (0.66 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 3 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration. Yellow crystals from ethanol; yield: 2.22 g (83%); m.p. >300°C. IR, ν: 3488-3337 (NH₃), 3056 (CH aromatic), 2988, 2893 (CH₃, CH₂), 2220 (CN), 1688 (CO), 1643 (C=N), 1629 (C=C). ¹H-NMR: Bull. Chem. Soc. Ethiop. 2018, 32(3).
δ: 1.13 (t, 3H, J = 6.79 Hz, CH₃), 4.21 (q, 2H, J = 6.79 Hz, CH₂), 4.93 (s, 2H, NH₂, D₂O exchangeable), 6.14 (s, 1H, pyridine H-4), 7.28-7.39 (m, 4H, C₆H₄). ¹³C NMR (DMSO): 16.3, 16.8 (two OCH₃CH₂), 52.4, 52.9 (two OCH₃CH₂), 116.4 (CN), 121.5, 122.9, 125.1, 127.2, 128.6, 138.4, 140.1, 142.6, 142.7 (pyridine, C₆H₄). Anal. calc'd for C₁₀H₁₀N₂O₂: C, 62.95; H, 4.97; N, 9.33%. Found: C, 64.32; H, 4.60; N, 9.97%. MS: m/z: (%) 135.2 (M⁺, 41%).

3-(1H-Benz[d]imidazol-2-yl)-2H-chromen-2-one (30)

To a solution of compound 3 (2.04 g, 0.01 mol) in ethanol (30 mL) containing piperidine (0.50 mL) salicylaldehyde (1.22 g, 0.01 mol) was added. The reaction mixture, in each case, was heated under reflux for 3 h then poured onto ice/water mixture containing few drops of hydrochloric acid and the formed solid product was collected by filtration. Yellow crystals from acetic acid; yield: 1.41 g (89%); m.p. 273°C. IR, v: 3559-3334 (OH), 3057 (CH aromatic), 1689 (CO), 1641 (C=N), 1633 (C=C). H-NMR: δ: 6.09 (s, 1H, coumarin H-4), 7.26-7.42 (m, 8H, 2C₆H₄), 8.09 (s, 1H, NH, D₂O exchangeable). ¹³C NMR (DMSO): 121.6, 122.4, 124.1, 125.3, 126.4, 126.8, 129.4, 130.3, 131.5 (C₆H₄, C₆H₄), 164.6 (CO), 173.4 (C=O); Anal. calc'd for C₁₀H₁₀N₂O₂: C, 73.27; H, 3.84; N, 10.68%. Found: C, 73.40; H, 3.94; N, 10.42%. MS: m/z: (%) 262 (M⁺, 16%).

General procedure for the synthesis of the annulated derivatives 32a, b

To a solution of compound 31 (2.62 g, 0.01 mol) in 1,4-dioxane containing triethylamine (0.50 mL) either α-chloroacetone (32a) (0.92 g, 0.01 mol) or ethyl α-chloroacetate (32b) (1.22 g, 0.01 mol) was added. The reaction mixture in each case was heated under reflux for 4 h then evaporated under vacuum. The remaining product, in each case, was triturated with ethanol and formed solid product was collected by filtration.

7-Methyl-1H-benzo[4,5]imidazo[1,2-a]chromeno[3,4-c]pyridin-1-one (32a). Green crystals from 1,4-dioxane; yield: 0.95 g (67%); m.p. 195°C. IR, v: 3056 (CH aromatic), 1687 (CO), 1640 (C=N), 1629 (C=C). H-NMR: δ: 2.93 (s, 3H, CH₃), 5.93 (s, 1H, pyridine H-4), 7.29-7.39 (m, 8H, 2C₆H₄). Anal. calc'd for C₁₀H₁₀N₂O₂: C, 75.99; H, 4.03; N, 9.59%. Found: C, 75.72; H, 3.83; N, 9.59%. MS: m/z: (%) 300 (M⁺, 36%).

7-Hydroxy-1H-benzo[4,5]imidazo[1,2-a]chromeno[3,4-c]pyridin-1-one (32b). Yellow crystals from acetic acid; yield: 1.40 g (82%); m.p. 217°C. IR, v: 3522-3341 (OH), 3057 (CH aromatic), 1689 (CO), 1642 (C=N), 1631 (C=C). H-NMR: δ: 5.90 (s, 1H, pyridine H-4), 7.26-7.41 (m, 8H, 2C₆H₄), 10.26 (s, 1H, OH, D₂O exchangeable). Anal. calc'd for C₁₀H₁₀N₂O₂: C, 71.52; H, 3.33; N, 9.27%. Found: C, 71.69; H, 3.46; N, 9.51%. MS: m/z: (%) 302 (M⁺, 40%).

8-Hydroxy-1H-benzo[4,5]imidazo[1,2-a]chromeno[3,4-c]pyridin-1-one (35)

To a solution of compound 31 (2.62 g, 0.01 mol) in 1,4-dioxane containing triethylamine (0.50 mL) either chloroacetyl chloride (1.12 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 4 h then evaporated under vacuum. The remaining product was triturated with ethanol and formed solid product was collected by filtration. Yellow crystals from acetic acid; yield: 2.55 g (69%); m.p. 263°C. IR, v: 3563-3319 (OH), 3055 (CH aromatic), 1688 (CO), 1640 (C=N), 1629 (C=C). H-NMR (DMSO-d₆): δ: 5.93 (s, 1H, pyridine H-4), 7.24-7.35 (m, 8H, 2C₆H₄), 10.28 (s, 1H, OH, D₂O exchangeable). ¹³C NMR (DMSO): 119.9, 120.3, 123.1, 123.6, 124.1, 124.3, 125.2, 127.6, 128.3, 129.4, 130.8, 140.6, 142.8, 143.2 (pyran, pyridine, 2C₆H₄), 163.8 (CO), 176.6 (C=O); Anal. calc'd for C₁₀H₁₀N₂O₂: C, 71.52; H, 3.33; N, 9.27%. Found: C, 71.72; H, 3.36; N, 9.66%. MS: m/z: 302 (M⁺, 40%).
3-(1-Acetyl-1H-benzo[d]imidazol-2-yl)-2H-chromen-2-one (37)

A solution of compound 31 (2.62 g, 0.01 mol) in acetic acid (10 mL) and acetic anhydride (5 mL) was heated under reflux for 3 h then evaporated under vacuum. The remaining product was triturated with diethyl ether and the formed solid product was collected by filtration. Yellow crystals from acetic acid; yield: 1.56 g (74%); m.p. 292 °C. IR, v: 3055 (CH aromatic), 1690, 1678 (CO), 1638 (C=N), 1632 (C=C). 1H-NMR: δ 2.80 (s, 3H, CH3), 6.23 (s, 1H, coumarin-H-4), 7.26-7.39 (m, 8H, 2C6H4). 13C NMR (DMSO): 119.3, 121.8, 123.1, 124.3, 125.0, 126.1, 127.6, 128.0, 129.4, 130.8, 140.3, 142.3, 143.8 (pyran, 2C). IR: 3349 (NH), 3055 (CH aromatic), 1689 (CO), 1638 (C=N), 1632 (C=C). MS: m/z 304 (M+), 28%. Anal. calcd for C21H16N2O3: C, 71.05; H, 3.97; N, 9.21%. Found: C, 71.33; H, 3.76; N, 9.38%. MS: m/z: (% 397 (M+), 32%).

2-(2-Oxa-2H-chromen-3-yl)-N-phenyl-1H-benzo[d]imidazole-1-carbothioamide (38)

To a solution of compound 31 (2.62 g, 0.01 mol) in ethanol (40 mL) containing triethylamine (0.50 mL) phenyl isothiocyanate (1.30 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 6 h then evaporated under vacuum. The remaining product was triturated with ethanol and formed solid product was collected by filtration. Pale yellow crystals from acetic acid; yield: 2.85 g (70%); m.p. 194 °C. IR, v: 3488-3349 (NH), 3055 (CH aromatic), 1689 (CO), 1638 (C=N), 1632 (C=C). 1H-NMR: δ 6.33 (s, 1H, coumarin-H-4), 7.26-7.38 (m, 13H, C6H5, 2C6H4), 8.31 (s, 1H, NH, D2O exchangeable). 13C NMR (DMSO): 119.3, 121.8, 122.6, 123.2, 123.8, 124.3, 125.3, 125.8, 126.4, 127.6, 128.5, 129.4, 130.8, 140.3, 142.6, 142.9. (pyran, C6H5, 2C6H4), 164.4 (CO), 176.3 (C=N); Anal. calcd for C34H27N3O6S: C, 69.50; H, 3.80; N, 10.57; S, 8.07%. Found: C, 69.79; H, 3.68; N, 10.41; S, 8.19%. MS: m/z: (% 304 (M+), 28%).

CONCLUSION

Ethyl 2-(1H-benzo[d]imidazol-2-yl)acetate (3) was used for several heterocyclic transformation reactions. The antitumor evaluations of the newly synthesized products toward the three cancer cell lines MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and SF-268 (CNS cancer) showed that compounds 5a, 9b, 9c, 17, 23b and 38 were of the highest potencies among the synthesized compounds. The work showed that benzimidazole derivatives were excellent compounds that can be used as anticancer agents.

REFERENCES

1. Irannjejad, H.; Amini, M.; Khodagholi, F.; Ansari, N.; Tusi, S.K.; Sharifzadeh, M.; Shafiee, A. Synthesis and in vitro evaluation of novel 1,2,4-triazine derivatives as neuroprotective agents. Bioorg. Med. Chem. 2010, 18, 4224-4230.
2. Catozzi, N.; Edwards, M.G.; Raw, S.A.; Wasnaire, P.; Taylor, R.K. Synthesis of the Louisianin alkaloid family via a 1,2,4-triazine inverse-electron-demand Diels-Alder approach. J. Org. Chem. 2009, 74, 8343-8354.
3. Laphookhieo, S.; Jones, S.; Raw, S.A.; Sainz, Y.F.; Taylor, R.J.K. Tandem oxidation processes for the regioselective preparation of 5-substituted and 6-substituted 1,2,4-triazines. Tetrahedron Lett. 2006, 47, 3865-3870.
4. Boger, D.L.; Panek, J.S.; Yasuda, M. Preparation and inverse-electron-demand Diels-Alder reaction of an electron-deficient heterocyclic azadiene: Triethyl 1,2,4-triazine-3,5,6-tricarboxylate and 2,3,6-tricarboxypyridine. Org. Synth. 1988, 66, 142-150.

Bull. Chem. Soc. Ethiop. 2018, 32(3)
5. Mohareb, R.M.; El-Sharkawy, K.; Sherif, S.M. The reaction of β-amino-α,γ-dicyanocrotononitrile with acetophenone: Synthesis of pyridine, pyrazidine and thiophene derivatives with antimicrobial activities. *Acta Pharm.* 2008, 58, 429-444.

6. Luo, Y.L.; Baathulaa, K.; Kannekanti, V.K.; Zhou, C.H.; Cai, G.X. Novel benzimidazole derived napthalimide triazoles: Synthesis, antimicrobial activity and interactions with calf thymus DNA. *Sci. China Chem.* 2015, 58, 483-494.

7. Sangshetti, J.N.; Dharmadhikari, P.P.; Chouthe, R.S.; Fatema, B.; Lad, V.; Karande, V.; Darandale, S.N.; Shinde, D.B. Microwave assisted nano (ZnO–TiO\(_2\)) catalyzed synthesis of some new 4,5,6,7-tetrahydro-6-(5-substituted-1,3,4-oxadiazo-2-yl) methylthieno[2,3-c]pyridine as antimicrobial agents. *Bioorg. Med. Chem. Lett.* 2013, 23, 2250-2253.

8. Witherington, J.; Bordas, V.; Garland, S.L.; Hickey, D.M.B.; Ife, R.J.; Liddle, J.; Saunders, M.; Smith, D.G.; Ward, R.W. 5-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). *Bioorg. Med. Chem. Lett.* 2003, 13, 1577-1580.

9. Shaker, Y.M.; Omar, M.A.; Mahmoud, K.; Elhallouty, S.M.; El-Senousy, W.M.; Ali, M.M.; Mahmoud, A.E.; Abdel-Halim, A.H.; Soliman, S.M.; El Diwani, H.I. Synthesis, in vitro and in vivo antitumor and antiviral activity of novel 1-substituted benzimidazole derivatives. *J. Enzyme Inhib. Med. Chem.* 2015, 30, 826-845.

10. Ahmadi, A. Synthesis and antibacterial evaluation of some novel manich bases of benzimidazole derivatives. *Bull. Chem. Soc. Ethiop.* 2016, 30, 421-425.

11. Ahmadi, A. Synthesis, characterization and antibacterial evaluation of some novel derivatives of 2-bromomethyl-benzimidazole. *Bull. Chem. Soc. Ethiop.* 2014, 28, 451-456.

12. Khoje, A.D.; Charnock, C.; Wan, B.; Franzblau, S.; Gundersen, L.L. Synthesis and antituberculosis activities of non-purine analogs of 6-aryl-9-benzylpurines: Imidazo-pyridines, pyrrolopyridines, benzimidazoles, and indoles. *Bioorg. Med. Chem.* 2011, 19, 3483-3491.

13. Singh, S.; Dwarakanath, B. S.; Mathew, T.L. DNA ligand Hoechst-33342 enhances UV induced cytotoxicity in human glioma cell lines. *J. Phytotax. Photobiol. B.* 2004, 77, 45-54.

14. Elzahabi, H.A.S. Synthesis, characterization of some benzazoles bearing pyridine moiety: Search for novel anticancer agents. *Eur. J. Med. Chem.* 2011, 46, 4025-4034.

15. Tseng, J.R.; Stuart, D.; Aardalen, K.; Kaplan, A.; Aziz, N.; Hughes, N.P.; Gambhir, S.S. Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor. *Neoplasia* 2011, 13, 266-275.

16. Reddy, T.R.; Reddy, G.R.; Reddy, L.S.; Jammula, S.; Lingappa, Y.; Kapavarapu, R.; Meda, C.L.; Parsa, K.V.; Pal, M. Montmorillonite K-10 mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4. *Eur. J. Med. Chem.* 2012, 48, 265-274.

17. Khaksar, S.; Yaghoobi, M. A concise and versatile synthesis of 2-amino-3-cyanopyridine derivatives in 2,2,2-trifluoroethanol. *J. Fluor. Chem.* 2012, 14, 41-44.